|Articles|April 1, 2001

April 2001
Volume 7
Issue 4

The Effect of Nonsteroidal anti-inflammatory Drugs on the Use of Gastroprotective Medication in People with Arthritis

Author(s)Kate L. Lapane, PhD, Joshua J. Spooner, PharmD, Dan Pettitt, DVM, MSc

Download PDF: The Effect of Nonsteroidal anti-inflammatory Drugs on the Use of Gastroprotective Medication in People with Arthritis

Articles in this issue

over 25 years ago

Article

Indirect Cost of Ischemic Heart Disease to Employers

over 25 years ago

Article

Cost-Sharing for Prescriptions of Sildenafil and Finasteride: A Case Study in Veteran Patients

over 25 years ago

Article

Effects of Compensation Method on Physician Behaviors

over 25 years ago

Article

Healthy Pregnancy Program in a National Managed Care Organization: Evaluation of Satisfaction and Health Behavior Outcomes

over 25 years ago

Article

Impact of Poorly Controlled Hypertension on Healthcare Resource Utilization and Cost

over 25 years ago

Article

Achieving Control of Diabetic Risk Factors in Primary Care Settings

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe

Related Content

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

ByJulie A. Patterson, PharmD, PhD,Roswell A. Cole, PharmD, MPH,Jonathan D. Campbell, PhD, MS,John Michael O’Brien, PharmD, MPH

July 9th 2026

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

ByVivian T. E. Tar, PharmD, MBA

July 8th 2026

The Effect of Nonsteroidal anti-inflammatory Drugs on the Use of Gastroprotective Medication in People with Arthritis

Articles in this issue

Related Content

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

Trending on AJMC

NYC Legionnaires Disease Cluster Slows as Cooling Tower Remediation Continues

Medicaid Fraud Crackdown Intensifies, But Is It Solving the Right Problem?

MS Likely Unfolds Along a Continuum Years Before First Symptoms

FDA Approves Gedatolisib for HR+/HER2- Advanced Breast Cancer

CVI Range Assessment Validated as Reliable Measure of Functional Vision in Children

Access, Affordability, & Accountability: A New Era in Oncology Reimbursement

The Effect of Nonsteroidal anti-inflammatory Drugs on the Use of Gastroprotective Medication in People with Arthritis

Articles in this issue

Related Content

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

Trending on AJMC

NYC Legionnaires Disease Cluster Slows as Cooling Tower Remediation Continues

Medicaid Fraud Crackdown Intensifies, But Is It Solving the Right Problem?

MS Likely Unfolds Along a Continuum Years Before First Symptoms

FDA Approves Gedatolisib for HR+/HER2- Advanced Breast Cancer

CVI Range Assessment Validated as Reliable Measure of Functional Vision in Children